Objective: To assess the importance of MAPT variant p.A152T in the risk of synucleinopathies.
Synucleinopathies are a diverse group of pathologically defined neurodegenerative diseases that present with abnormal accumulation of the protein a-synuclein in glial cells and neurons. 1 Synucleinopathies occur in 3 main types: Parkinson disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). 2 PD and DLB cases that present with Lewy body inclusions at pathology can be further categorized as Lewy body disease (LBD). 2 PD is the most common synucleinopathy and more than 25 independent risk loci have been associated with disease through large genome-wide association approaches. 3 The microtubuleassociated protein tau gene (MAPT) is one of the most replicable associations with susceptibility to PD. [3] [4] [5] Mutations in MAPT were first discovered as causing frontotemporal dementia (FTD) with parkinsonism linked to chromosome 17. 6 MAPT causal mutations were shown to disrupt Supplemental data at Neurology.org the protein resulting in abnormal tau accumulation. 7 They have been implicated in several tauopathies, including Alzheimer disease (AD) and FTD spectrum disorders.
A rare MAPT variant p.A152T was first identified in a patient with an unusual tauopathy phenotype at autopsy. 8 Subsequently, it was demonstrated through a case-control study of over 15,000 subjects that p.A152T substitution conferred an increased risk to tauopathies. 9 A small series of patients with PD were included in this previous study (662 patients with PD, 176 patients with LBD) and although not statistically significant the results showed a trend toward increased risk. Given these findings, we set out to assess the importance of the MAPT p.A152T variant in susceptibility to clinical PD, DLB, MSA, and pathologically defined LBD.
METHODS Study subjects. A total of 3,229 patients with clinical PD, 442 with clinical DLB, 181 with MSA, 832 with LBD, and 2,456 controls were included in this case-control study. These were all subjects in the aforementioned disease groups with available genetic DNA. The clinical diagnoses were established according to the consensus criteria for PD, 10 DLB, 11 and MSA. 12 All subjects were unrelated non-Hispanic Caucasians of European descent. Patients with clinical PD and controls are from a US series collected at Mayo Clinic's 3 campuses (Jacksonville, 893 cases and 1,370 controls; Rochester, 854 cases and 176 controls; and Scottsdale, 126 cases and 50 controls; and 83 patients from the Mayo Clinic Florida Brain Bank: total 1,873 patients, 1,679 controls), a Polish series (825 patients, 362 controls), an Irish series (366 patients, 371 controls), a Swedish series (122 patients, 44 controls), a Czech series (33 patients), and a Ukrainian series (10 patients). In the US series, 656 cases and 1,325 controls are part of the previous study that associated MAPT p.A152T with tauopathies. 9 Our DLB series (442 samples) and MSA series (181 samples; 94 are pathologically confirmed) also consist of samples collected at Mayo Clinic. Our LBD cases series (832 non-Hispanic Caucasian patients) is a pathologically defined series collected and examined at Mayo Clinic Jacksonville and categorized according to the Consortium on Dementia with Lewy bodies (CDLB) pathologic criteria of low, intermediate, or high likelihood of having clinical DLB based on the severity of coexisting AD pathology (measured by Braak tangle stage). 13, 14 A total of 115 patients with LBD were part of the aforementioned study involving p.A152T and tauopathies. 9 Characteristics of patients with PD, DLB, MSA, LBD, and controls are summarized in table 1 for each series. Controls were individuals free of PD or a related movement disorder at the time of examination.
Standard protocol approvals, registrations, and patient consents. The Mayo Clinic institutional review board approved the study, each individual site received local institutional review board approval, and all subjects provided written informed consent.
Genetic analysis. Genomic DNA was extracted from peripheral blood monocytes or brain tissue using standard protocols. 15 Genotyping of MAPT exon 7 variant rs143624519 (NM_005910.5; c.454G.A, p.A152T) was performed using a custom TaqMan Allelic Discrimination Assay on an ABI 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions (primer sequences are available upon request). Genotype calls were made using SDS 2.2.2 software. Carrier status was confirmed using standard Sanger sequencing methods. Statistical analysis. Frequencies of MAPT p.A152T were compared between controls and the different disease groups using univariate logistic regression models. For the DLB, LBD, and MSA patient groups, comparisons with controls involved only controls from the US series given that these disease groups were also exclusively from the United States. Odds ratios (ORs) and 95% confidence intervals were estimated. There was no evidence of a departure from Hardy-Weinberg equilibrium in controls for any of the series (all x 2 p . 0.05). We did not adjust these models for age or sex as this additional model complexity would not be appropriate for this rare variant. p Values of 0.05 or lower were considered statistically significant. All statistical analyses were performed using PLINK (version 1.07) (http://pngu.mgh. harvard.edu/purcell/plink/). 16 RESULTS Our previous genetic study on the role of MAPT p.A152T in different neurodegenerative diseases included 15,369 subjects, including 656 patients with PD and 1,325 healthy controls in our current series. 9 These data suggested a tendency toward increased risk conferred by the MAPT p.152T allele in patients with clinical PD, but this finding was not statistically significant (OR 2.03, p 5 0.32, table 2, old series). In order to assess the importance of this allele as a risk factor for PD, we genotyped the variant in a larger series of US and European subjects (total combined series 3,229 patients with PD, 2,456 controls). We detected 18 PD and 10 control heterozygotes for variant p.A152T; no homozygous carriers were detected. The MAF was 0.28% in patients with PD and 0.20% in controls, which is similar to the European Exome Variant Server MAF (0.27%) and the Exome Aggregation Consortium (0.17%). Table 2 displays a comparison of the frequency of variant p.A152T between patients with PD and controls. Although not statistically significant, risk of PD was higher for the p.152T allele carriers in the US series (OR 1.80, p 5 0.34) and the Irish series (OR 1.79, p 5 0.36). However, a nonsignificant protective association was observed in the Polish series (OR 0.66, p 5 0.65), and when combining the series there was no notable association between allele p.152T and PD risk (OR 1.37, p 5 0.42). . In the multiple system atrophy series, information was unavailable regarding age at onset (n 5 124). In the dementia with Lewy bodies series, information was unavailable regarding age at study (n 5 198) and age at dementia with Lewy bodies onset (n 5 4). In the LBD series, information was unavailable regarding age at death (n 5 1 low CDLB likelihood patient).
The screening of our DLB series (442 patients) identified 6 patients with the p.152T allele, which translates into a MAF of 0.68% (one of these 6 patients is also included in the LBD series). Comparing this frequency to the MAF of the US controls (0.12%) results in an OR of 5.76 (p 5 0.007), suggesting that p.152T is a significant risk factor for DLB (table 2) . Additionally, we detected 2 carriers in our MSA series, one of which is a pathologically confirmed case (of mixed clinical presentation with cerebellar and parkinsonian phenotype) and one is a clinical case (MSA with predominant parkinsonism). The MAF in the MSA series is 0.55%, which results in an OR of 4.68 when compared to US controls (p 5 0.08) (table 2). It is important to point out that this finding is not statistically significant and therefore should be interpreted with caution; however, the high OR supports further study of MAPT p.A152T as a risk factor for MSA.
As part of the previous study, 176 patients with LBD had been screened for p.A152T and the p.152T allele had not been detected. We screened the variant in our new expanded LBD series (832 cases, of which 115 samples were part of the first study, and 72 samples overlap with the DLB series, including one p.152T carrier) stratified according to the CDLB classification. The results of the association tests (compared to US clinical controls) are presented in table 3. Our results suggest a significantly increased frequency in total LBD, where a MAF 0.42% was observed in LBD cases compared to 0.12% in US controls (OR 3.55, p 5 0.04). The risk is significantly increased in LBD cases with intermediate CDLB (OR 4.99, p 5 0.04). The frequency of p.A152T was also higher in the high CDLB group, but this was not statistically significant and should therefore be viewed cautiously (OR 3.61, p 5 0.09). No notable difference in the frequency of p. A152T was observed between the low CBLD patients and controls (OR 1.86, p 5 0.58). Although Braak tangle stage is used along with neuroanatomical predominance of Lewy body pathology to formulate the CDLB likelihood, 14 we did not observe differences in hippocampal and cortical density measures of neurofibrillary tangles, amyloid-b plaques, or Lewy body counts between total LBD carriers and noncarriers. We also compared different demographic and neuropathologic characteristics between LBD carriers and noncarriers of p.152T but did not observe any significant differences. Results of these analyses are presented in table e-1 on the Neurology ® Web site at Neurology.org. As previously mentioned, we did not adjust our regression models for age or sex given that this additional model complexity would be questionable for a rare variant with our sample size. However, in order to address the possibility that differences in age and sex between case and control groups could have influenced our results, we examined descriptive summaries of allele frequencies when stratifying by age and sex in the 2 disease groups for which a significantly different frequency of p.A152T was observed in comparison to controls (DLB and LBD). As shown in table e-2, the aforementioned increased frequencies of MAPT p.A152T in DLB and LBD were generally consistent across age and sex subgroups.
DISCUSSION The MAPT p.A152T substitution has been recognized to confer an increased risk to tauopathies and the common MAPT H1 haplotype has been associated with increased risk of synucleinopathies. 9, 17 We screened a series of patients with clinical PD, DLB, MSA, and controls (over 5,000 subjects), as well as 832 LBD cases, for the MAPT p.A152T substitution. We did not detect any significant effect of the p.152T allele in clinical PD but our results show that the variant is associated with DLB (OR 5 5.76) and LBD (OR 5 3.55). We did not observe a statistically significant difference in the frequency of p.A152T between patients with MSA and controls, but the high estimated OR suggests that further study of the role of MAPT p.A152T in risk of MSA is warranted.
The frequencies between our different clinical PD series appear to vary with a substantial 5-fold difference in MAF between Irish and US controls. This might be due to sampling bias but could also reflect population-specific heterogeneity at the MAPT locus; additional studies are warranted to study this phenomenon. The p.A152T variant sits on the MAPT H1 haplotype, which is associated with PD. 17 The OR of the H1 haplotype in the largest PD genomewide association study meta-analysis is 1.3, 3 which is typical for an individual locus in complex disease. The risk at the MAPT locus could be explained by the cumulative effect of several rare coding alleles such as p.152T or by common low penetrance small effect variants located most likely in less explored genomic regions such as intergenic or intronic sequences. Our results suggest that MAPT p.A152T is not directly involved in the risk of clinical PD. However, we cannot exclude a true risk effect based on 95% confidence limits for the OR estimate in the overall PD case-control sample, and therefore larger studies are needed to further elucidate the role of this rare variant in susceptibility to PD.
We detected 6 carriers in our DLB series (n 5 442) and 7 carriers in our LBD series (n 5 832) compared to 4/1,679 in our US controls, which shows an increased risk. The proportion of carriers was also higher in our MSA series compared to controls, but this was not significant and requires confirmation in larger series. Our CDLB-stratified analysis suggests that the risk is increased in intermediate and also potentially in high CDLB. These findings would appear to support the association with clinical DLB, and may in part be influenced by the interrelationship of coexisting LBD and AD pathology. A recent candidate gene association study in DLB failed to find a statistically significant association with the common MAPT H1 haplotype, although nominal association was observed. 18 Our previous study including 61 patients with pathologically confirmed MSA suggests that MAPT H1 haplotype is associated with disease risk. 19 These findings and the present study further suggest that there are distinct genetic risk factors between the synucleinopathies, PD, DLB, and MSA. Due to the low frequency of the MAPT p.A152T variant, the possibility of type II error (i.e., a false-negative association) is important to consider, and emphasis is best placed on 95% confidence limits when interpreting the results of comparisons between controls and the different disease groups with regard to the frequency of p.A152T. Larger studies and meta-analytic approaches will be needed to evaluate the role of this rare variant in susceptibility to a-synucleinopathies with more precision.
The functional consequences of the p.A152T substitution are not completely understood. MAPT has a threonine phosphorylation site at position 153. It has been speculated that p.152T creates a new phosphorylation site that contributes to tau hyperphosphorylation. 20 The increased phosphorylation could explain the observed reduction in microtubule assembly in p.A152T mutants. 9 Beyond some overlapping clinical presentation between tauopathies, such as AD, and synucleinopathies, such as PD and DLB-dementia, for example, can be a feature of PD (PD dementia) and DLB-it is increasingly acknowledged that an overlap exists between the pathologic presentations of these disorders. Proteins tau and a-synuclein have both been observed in brain inclusions in the 2 types of diseases. 21 Phosphorylated tau has been detected in synaptic enriched fractions of frontal cortex from patients with LBD 22 and tau-positive inclusions have been reported in families with dominantly inherited PD caused by mutations in the a-synuclein gene (SNCA). 23 Furthermore, it has been shown that tau and a-synuclein synergistically promote the polymerization of each other in vitro. 24 The overlapping pathologies could be interpreted as an indication that some molecular pathways involved in these disease pathogeneses are the same and that MAPT p.A152T is a risk factor in several neurodegenerative diseases and acts to influence cell death through promotion of protein aggregation, a toxic gain of function.
We show that the MAPT p.152T allele confers risk to specific synucleinopathies but additional studies are warranted to clarify the role of MAPT variation in clinical PD and to further characterize the role of MAPT p.152T in risk of DLB, MSA, and LBD.
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